Preclinical Testing News and Research

RSS

Mouse model of fatal COVID-19 developed for vaccine and drug testing

Now, a new study published on the preprint server bioRxiv in July 2020 presents an engineered transgenic mouse that reproduces the functional and clinical characteristics of severe human SARS-CoV-2 infection.

21 Jul 2020

Altimmune announces positive preclinical results of intranasal COVID-19 vaccine candidate

Altimmune, Inc., a clinical-stage biopharmaceutical company, has announced positive results from the preclinical studies conducted in mice at the University of Alabama at Birmingham of its intranasal COVID-19 vaccine candidate, AdCOVID.

13 Jul 2020

New platform prioritizes synergistic drug combinations against SARS-CoV-2

Researchers in the U.S. have used a new web-based platform to help identify synergistic and antagonistic drug combinations and their underlying mechanisms of action in the context of coronavirus disease 2019 (COVID-19).

2 Jul 2020

Scientists find potential new way to improve treatment for Von Willebrand Disease

Scientists have found a potential new way to promote blood clotting that could be used to help develop treatments for Von Willebrand Disease, the most common genetic bleeding disorder.

12 Jun 2020

Vaccine design can face specific challenges, say researchers

The goal of a vaccine is to trigger a response that safely protects against an infection and/or the burden of disease.

13 May 2020

New nasopharyngeal swabs move into human trials for COVID-19

Researchers at the Wyss Institute at Harvard University, in collaboration with healthcare, research, and industrial partners, have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the nationwide and international shortage of swabs for COVID-19 testing and research.

28 Apr 2020

Scientists elucidate novel disease processes involved in pulmonary fibrosis development

Working alongside research groups from Heidelberg, researchers from Charité - Universitätsmedizin Berlin have elucidated the novel disease processes involved in the development of pulmonary fibrosis.

27 Apr 2020

Potential universal Ebola vaccine may neutralize all four harmful virus species

Infectious disease scientists report early development of a potential universal vaccine for Ebola viruses that preclinical tests show might neutralize all four species of these deadly viruses infecting people in recent outbreaks, mainly in Africa.

16 Apr 2020

UAB will collaborate with Altimmune to test a COVID-19 vaccine candidate

The University of Alabama at Birmingham is launching a collaboration with the biopharmaceutical company Altimmune, Inc. for preclinical testing of a potential vaccine to prevent COVID-19 disease.

30 Mar 2020

How long to a coronavirus vaccine?

The whole world is waiting for one. A vaccine is the only thing that could conceivably save the world from a horrifying cascade of deaths, other than a miracle, it seems.

29 Mar 2020

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.

5 Mar 2020

Novel compounds show promise as potent new treatment for malaria

A novel class of antimalarial compounds that can effectively kill malaria parasites has been developed by Australian and US researchers.

4 Mar 2020

Study exposes the Achilles' heel of deadly ccRCC tumors

An experimental drug already shown to be safe and help some patients with clear cell renal cell carcinoma, a deadly form of kidney cancer, effectively disables its molecular target.

20 Feb 2020

Protein Data Bank archive releases new coronavirus protease structure

The Protein Data Bank archive, which contains more than 160,000 3D structures for proteins, DNA, and RNA, this month released a new Coronavirus protease structure following the recent coronavirus outbreak, an ongoing viral epidemic primarily affecting mainland China that now threatens to spread to populations in other parts of the world.

10 Feb 2020

The challenge of new antibiotic discovery

It is important to discover antibiotic drugs and to bring them to clinical use, a task made all the more urgent by the increase in the number of infections that are resistant to existing antibiotics. However, this task is a formidable one.

28 Jan 2020

Human organ chips for better drug development

The process of developing new drugs is both difficult and costly. It is estimated that of all the drug candidates which start out on their testing journey, less than 14% actually make it to the clinical scene and receive approval by the US Food and Drug Administration (FDA).

27 Jan 2020

Study shows superior functionality of Duodenum Intestine-Chip populated with organoids

Emulate, Inc. announced today a published study in collaboration with Johns Hopkins University School of Medicine, that demonstrated superior functionality of the Duodenum Intestine-Chip populated with organoids, compared to organoids alone.

14 Jan 2020

Novoheart collaborates with AstraZeneca to develop world’s first human heart-in-a-jar model of heart failure

Novoheart, a global stem cell biotechnology company, is pleased to announce a collaboration with global biopharmaceutical company AstraZeneca, in an effort to develop the world’s first human-specific in vitro, functional model of heart failure with preserved ejection fraction (HFpEF), a common condition especially among the elderly and in women, with the reported prevalence approaching 10% in women over the age of 80 years.

26 Nov 2019

New wearable, implantable devices may revolutionize treatment for kidney failure patients

A feature article appearing in an upcoming issue of CJASN highlights the potential of wearable and implantable devices for treating kidney failure.

14 Nov 2019

Sanford Burnham Prebys scientist receives $3.58 million to advance treatment for opioid-use disorders

The National Institute on Drug Abuse, part of the National Institutes of Health, awarded a $3.58 million grant to Sanford Burnham Prebys scientist Anthony Pinkerton, Ph.D., to advance a potential treatment for opioid-use disorders, called SBI-553.

23 Oct 2019